ArticleJournal of the Pediatric Infectious Diseases Society2026
Cerebrospinal Pharmacokinetic and Pharmacodynamic Evaluation of Sulbactam: Dosing Considerations for Acinetobacter baumannii Meningitis in Pediatric Patients.
Article in Journal of the Pediatric Infectious Diseases Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundEffective sulbactam dosing regimens for treating Acinetobacter baumannii meningitis in pediatric patients, considering the degree of cerebrospinal fluid (CSF) inflammation and its consequent effect on drug penetration, have not been thoroughly studied. This study aimed to describe a cerebrospinal pharmacokinetic (PK) model of sulbactam and propose a dosing strategy in pediatric patients based on pharmacodynamic (PD) evaluation with stochastic simulation.
methodsPublications were systematically extracted from MEDLINE for sulbactam CSF PK data collection. A cerebrospinal PK model was described using CSF samples and applied to estimate the probability of attaining the PK/PD target (60% time above the minimum inhibitory concentration [T > MIC] in CSF). The cerebrospinal PK/PD breakpoint was defined as the highest MIC at which the target attainment probability in CSF was ≥90% for each age group (infants [4 weeks to 11 months], children [1-6 years], and pediatrics [7-16 years]). RESULTS AND DISCUSSION: The study population included 21 pediatric patients aged 0.083-13.5 years. The CSF/serum concentration ratio at the various sampling points ranged 0.002-0.695. Based on the result of covariate analysis, CSF protein and CSF glucose levels were incorporated into the CSF-to-serum partition coefficient. The visual predictive check of CSF concentrations indicated no major bias. Regarding the cerebrospinal PK/PD evaluation, in infants and children groups with meningeal inflammation (eg, CSF protein > 100 mg/dL and CSF glucose < 40 mg/dL) a sulbactam dose of 200 mg/kg/day (as sulbactam component) with 0.5-h infusion was required to achieve 90% probability of CSF target attainment (60% T > MIC) up to an MIC of 4 μg/mL for A. baumanii.
conclusionsThis study identified effective dosing regimens for A. baumannii meningitis in pediatric patients in consideration of the degree of inflammation in CSF. High-dose sulbactam regimens can be considered to optimize CSF target attainment for A. baumannii meningitis in pediatric patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.